Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...

A new pill called Enlicitide may help people who don’t get results from statins. The drug showed big drops in bad cholesterol ...

High cholesterol is a major driver of heart disease. Statins, like Lipitor and Zocor, emerged as powerful antidotes starting in the 1980s. With blood-pressure medicines, antismoking campaigns and ...

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...